BlossomHill Therapeutics (NASDAQ:BLSM – Get Free Report) had its target price increased by analysts at Leerink Partners from $36.00 to $40.00 in a report issued on Monday, Benzinga reports. The firm presently has an “outperform” rating on the stock. Leerink Partners’ price target indicates a potential upside of 56.86% from the stock’s current price.
BLSM has been the subject of several other reports. Wall Street Zen upgraded shares of BlossomHill Therapeutics to a “hold” rating in a research report on Saturday, August 15th. Zacks Research upgraded shares of BlossomHill Therapeutics to a “hold” rating in a research report on Wednesday, September 2nd. HC Wainwright started coverage on shares of BlossomHill Therapeutics in a research note on Tuesday, September 1st. They set a “buy” rating and a $35.00 price target on the stock. Guggenheim boosted their price objective on shares of BlossomHill Therapeutics from $30.00 to $40.00 and gave the company a “buy” rating in a research report on Monday. Finally, JPMorgan Chase & Co. initiated coverage on BlossomHill Therapeutics in a research note on Tuesday, September 1st. They issued an “overweight” rating and a $28.00 price objective for the company. Five research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, BlossomHill Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $35.00.
Check Out Our Latest Analysis on BLSM
BlossomHill Therapeutics Trading Down 0.9%
BlossomHill Therapeutics (NASDAQ:BLSM – Get Free Report) last posted its earnings results on Friday, September 18th. The company reported ($8.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by ($7.91). Equities analysts expect that BlossomHill Therapeutics will post -3.86 earnings per share for the current year.
Insider Transactions at BlossomHill Therapeutics
In related news, Director Bihua Chen purchased 312,500 shares of BlossomHill Therapeutics stock in a transaction on Monday, August 10th. The shares were bought at an average cost of $16.00 per share, for a total transaction of $5,000,000.00. Following the acquisition, the director owned 3,614,034 shares in the company, valued at approximately $57,824,544. The trade was a 9.47% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Orbimed Advisors Llc purchased 625,000 shares of BlossomHill Therapeutics stock in a transaction on Monday, August 10th. The stock was bought at an average price of $16.00 per share, for a total transaction of $10,000,000.00. Following the completion of the acquisition, the director owned 2,714,279 shares in the company, valued at $43,428,464. The trade was a 29.91% increase in their position. The SEC filing for this purchase provides additional information. In the last three months, insiders have bought 1,573,900 shares of company stock valued at $25,181,900.
BlossomHill Therapeutics Company Profile
BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company’s lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.
Featured Articles
- Five stocks we like better than BlossomHill Therapeutics
- Can Bloom Energy Pop the Top Off AI’s Massive Energy Bottleneck?
- Coach’s Momentum Powers Tapestry Despite the Stock’s Sharp Pullback
- AI Is Reshaping SaaS—These 2 Software ETFs Offer Different Ways to Play It
- Insiders Signal Deep Value In DICK’s Sporting Goods
Receive News & Ratings for BlossomHill Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BlossomHill Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
